Enzalutamide induced acute generalized exanthematous pustulosis

INTRODUCTION: Enzalutamide (Xtandi®) is a new potent inhibitor of the signaling pathway for the androgen receptor with a half-life of 5.8 days. It has been on the market for the treatment of metastatic castration-resistant prostate cancer since November 2013. OBJECTIVE: We report the first case of a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Dermatol Case Rep
Autors principals: Alberto, Chloé, Konstantinou, Maria Polina, Martinage, Catherine, Casassa, Eline, Tournier, Emilie, Bagheri, Haleh, Sibaud, Vincent, Mourey, Loïc, Mazereeuw-Hautier, Juliette, Meyer, Nicolas, Paul, Carle, Bulai Livideanu, Cristina
Format: Artigo
Idioma:Inglês
Publicat: Specjalisci Dermatolodzy 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5124370/
https://ncbi.nlm.nih.gov/pubmed/27900064
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3315/jdcr.2016.1226
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars